Significance and quality control of detection of four blood-borne diseases before transfusion and operation

doi:10.3877/cma.j.issn.2095-5820.2015.04.003

Abstract

Abstract:

Screening for hepatitis B virus, hepatitis C virus, human immunodeficiency virus, and treponema pallidum prior to transfusion and operation plays an important role in avoiding nosocomial transmission of the aforementioned pathogens due to transfusion or operation, circumventing medical disputes and early finding infected persons. However, the detection performances of related infection indicators for the pathogens differ greatly among different medical institutions. Thus, the article intends to develop reasonable and efficient strategies for detecting the above four pathogens by briefly reviewing clinical significances of the related parameters, the detection principles and performances, as well as the common detection strategies used at home and abroad.

Key words: Transfusion, Infection detection, Nosocomial infection, Quality control

Jing Peng, Ziyong Sun. Significance and quality control of detection of four blood-borne diseases before transfusion and operation[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2015, 03(04): 202-206.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcsysgldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5820.2015.04.003

https://zhlcsysgldzzz.cma-cmc.com.cn/EN/Y2015/V03/I04/202

References 50

[1]	韩选伟, 胡同平, 张文兰. 10681例输血前、术前、产前患者感染性疾病标志物检查结果分析[J]. 中国医学创新, 2012, 9(5):71–72.
[2]	王斌, 张录喜, 李红, 刘瑞红, 等. 12870例术前和输血前四项传染病指标检测结果及意义[J]. 当代医学, 2012, 18(11):18–19.
[3]	王海滨, 石新慧. 输血前四项感染指标联合测定的结果分析[J]. 中华实验和临床感染病杂志(电子版), 2013, 7(2):269–271.
[4]	王友新, 钟瑜, 黄玉香. 输血前四项感染性指标检测的临床价值[J]. 临床和实验医学杂志, 2011, 10(5):373.
[5]	杨慧. 受血者输血前四项传染性指标检测3216例分析[J]. 上海预防医学, 2010, 22(4):190–191.
[6]	吴来林. 5783例创伤患者手术前4项血液传染病指标检测情况分析[J]. 浙江创伤外科, 2014, 19(6):996–997.
[7]	林甲进, 朱碎永, 张瑛. 患者输血前血液传播性疾病检测意义的探讨[J]. 中华医院感染学杂志, 2001, 11(5):365,397.
[8]	叶贤林, 柏景乔. 无偿献血人群低水平乙肝感染情况调查分析[J]. 中国预防医学杂志, 2007, 8(3):183–185.
[9]	La’ulu SL, Roberts WL. The analytic sensitivity and mutant detection capability of six hepatitis B surface antigen assays[J]. Am J Clin Pathol, 2006, 125(5):748–751.
[10]	Moerman B, Moons V, Sommer H, et al. Evaluation of sensitivity for wild type and mutant forms of hepatitis B surface antigen by four commercial HBsAg assays[J]. Clin Lab, 2004, 50(3–4):159–162.
[11]	Scheiblauer H, Soboll H, Nick S. Evaluation of 17 CE-marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection[J]. J Med Virol, 2006, 78 Suppl 1:S66–70.
[12]	Sommese L, Sabia C, Paolillo R, et al. Screening tests for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus in blood donors: evaluation of two chemiluminescent immunoassay systems[J]. Scand J Infect Dis, 2014, 46(9):660–664.
[13]	Verheyen J, Neumann-Fraune M, Berg T, et al. The detection of HBsAg mutants expressed in vitro using two different quantitative HBsAg assays[J]. J Clin Virol, 2012, 54(3):279–281.
[14]	田拥军, 覃莉, 刘慎沛, 等. 8种国产HBsAg试剂盒检测变异HBsAg的效果评价[J]. 临床检验杂志, 2007, 25(4):250–252.
[15]	Peng J, Cheng L, Yin B, et al. Development of an economic and efficient strategy to detect HBsAg: application of "gray-zones" in ELISA and combined use of several detection assays[J]. Clin Chim Acta, 2011, 412(23–24):2046–2051.
[16]	Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection[J]. J Hepatol, 2008, 49(4):652–657.
[17]	Raimondo G, Caccamo G, Filomia R, et al. Occult HBV infection[J]. Semin Immunopathol, 2013, 35(1):39–52.
[18]	Raimondo G, Pollicino T, Cacciola I, et al. Occult hepatitis B virus infection[J]. J Hepatol, 2007, 46(1):160–170.
[19]	Morales-Romero J, Vargas G, Garcia-Roman R. Occult HBV infection: a faceless enemy in liver cancer development[J]. Viruses, 2014, 6(4):1590–1611.
[20]	Taira R, Satake M, Momose S, et al. Residual risk of transfusion-transmitted hepatitis B virus (HBV) infection caused by blood components derived from donors with occult HBV infection in Japan[J]. Transfusion, 2013, 53(7):1393–1404.
[21]	史德莹, 冬李, 汤晓雨, 等. 术前患者血清传染性指标和HBsAb检测结果分析[J]. 中国社区医师(医学专业), 2010, 35(12):166–167.
[22]	王凯. HBsAb免疫保护特性对降低HBV输血传染风险的作用[J]. 医药论坛杂志, 2013, 8:145–146.
[23]	赵磊. 探讨利用HBsAb免疫保护特性降低HBV输血传染风险[J]. 中国输血杂志, 2012, 25(Si):188.
[24]	Cheng L, Guan Q, Zhang J, et al. Discrepancies between two automated immunoassay systems in determining hepatitis B virus markers in serum samples with concomitant presence of antigens and antibodies[J]. Ann Clin Lab Sci, 2010, 40(1):49–52.
[25]	Zhang JM, Xu Y, Wang XY, et al. Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection[J]. Clin Infect Dis, 2007, 44(9):1161–1169.
[26]	Protzer-Knolle U, Naumann U, Bartenschlager R, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation[J]. Hepatology, 1998, 27(1):254–263.
[27]	Hsu HY, Chang MH, Liaw SH, et al. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan[J]. Hepatology, 1999, 30(5):1312–1317.
[28]	Colson P, Borentain P, Motte A, et al. Clinical and virological significance of the co-existence of HBsAg and anti-HBs antibodies in hepatitis B chronic carriers[J]. Virology, 2007, 367(1):30–40.
[29]	Zhang Z, Li L, Tian Y, et al. HBsAg/HBsAb double positive hepatitis B virus infection model in vitro and in vivo[J]. J Huazhong Univ Sci Technolog Med Sci, 2009, 29(5):575–579.
[30]	Seo SI, Choi HS, Choi BY, et al. Coexistence of hepatitis B surface antigen and antibody to hepatitis B surface may increase the risk of hepatocellular carcinoma in chronic hepatitis B virus infection: a retrospective cohort study[J]. J Med Virol, 2014, 86(1):124–130.
[31]	Laperche S, Nubling CM, Stramer SL, et al. Sensitivity of hepatitis C virus core antigen and antibody combination assays in a global panel of window period samples[J]. Transfusion, 2015, 55(10):2489–2499.
[32]	Wu S, Liu Y, Cheng L, et al. Clinical evaluation of the signal-to-cutoff ratios of hepatitis C virus antibody screening tests used in China[J]. J Med Virol, 2011, 83(11):1930–1937.
[33]	Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep, 2003, 52(RR-3):1–13,5; quiz CE1–4.
[34]	CDC. Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep, 2013, 62(18):362–365.
[35]	黄建生, 主编. 丙型肝炎[M]. 北京:人民军医出版社, 2013:306–352.
[36]	彭文伟, 主编. 传染病学[M]. 6版. 北京:人民卫生出版社, 2004:25.
[37]	Malm K, von Sydow M, Andersson S. Performance of three automated fourth-generation combined HIV antigen/antibody assays in large-scale screening of blood donors and clinical samples[J]. Transfus Med, 2009, 19(2):78–88.
[38]	常俊峰. 三种HIV抗原／抗体检测方法对HIV早期感染检测的诊断研究[J]. 中国免疫学杂志, 2015, 31(8):1082–1084.
[39]	吉阳涛, 韩晓旭, 欧阳金鸣, 等. 三种四代HIV筛查试剂检测窗口期的差异研究[J]. 中华检验医学杂志, 2014, 37(8):613–616.
[40]	贾向东. 三种HIV抗体初筛方法的比较[J]. 临床输血与检验, 2010, 12(3):260.
[41]	李秀华, 许四宏, 宋爱京, 等. 4种国产和3种进口第4代HIV抗原抗体检测试剂的质量评价[J]. 中华微生物学和免疫学杂志, 2011, 31(9):847–850.
[42]	梅志锋, 朱晓华, 王剑甦. 三种HIV抗体初筛方法的比较[J]. 疾病监测与控制, 2011, 10(5):630–631.
[43]	欧阳金鸣, 韩晓旭, 吉阳涛, 等. 三种不同技术原理的第4代HIV诊断试剂的临床检测性能比较研究[J]. 中华检验医学杂志, 2013, 36(10):903–907.
[44]	性病与艾滋病中心. 二〇一三年全国艾滋病病毒抗体诊断试剂临床质量评估报告. 2013. URL
[45]	杨坤, 淑燕, 黄新宝. ELISA 法与胶体金法检测血液抗-HIV 结果对比分析[J]. 医药前沿, 2012, 2(17):187–188.
[46]	朱柏林. 金标层析法与酶联免疫吸附试验初筛 HIV1+2型抗体对比分析[J]. 检验医学与临床, 2014, 11(10):1341–1346.
[47]	Janier M, Hegyi V, Dupin N, et al. 2014 European guideline on the management of syphilis[J]. J Eur Acad Dermatol Venereol, 2014, 28(12):1581–1593.
[48]	刘兵, 冯文莉. 梅毒实验室检测方法的研究进展[J]. 中国医药指南, 2015, 13(7):48–50.
[49]	文海燕, 张华荣, 陈正明, 等. 梅毒检测方法的研究进展[J]. 中国皮肤性病学杂志, 2012, 26(4):354–356,360.
[50]	魏万惠, 尹跃平, 王红春, 等. 2006-2008年全国梅毒血清学检测室间质评结果分析[J]. 中华皮肤科杂志, 2013, 46(5):353–355.

Please choose a citation manager

Content to export